InflaRx As Amgen’s competing therapy has come under growing regulatory scrutiny, an opportunity has emerged for InflaRx N.V. to position its own oral C5aR inhibitor in the market. The Jena-based biotech company is now moving quickly to capitalise on that opening: InflaRx is refocusing its pipeline on severe renal diseases while simultaneously advancing a US$150m capital raise intended to fund development through key clinical milestones.
Tag Archive for: Amgen
Getty Images for Unsplash+Denmark-based Lundbeck has reported positive top-line results from the intravenous arm of its phase IIb PROCEED trial of bocunebart (Lu AG09222) in migraine prevention, putting the neuroscience specialist on course for phase III discussions with regulators. The milestone comes after the company was forced to abandon the drug’s subcutaneous formulation last year — a setback that had cast a shadow over the entire PACAP-targeting approach.
The European Commission has approved Amgen’s Uplizna in generalized myasthenia gravis, moving the big biotech into a market served by argenx, Johnson & Johnson and UCB.
Genentech Corp. / RocheThe new year at Cologne-based Disco Pharma has begun much as the old one ended: with a headline-grabbing announcement. Just weeks after closing a sizeable financing round, the company has now unveiled an equally notable collaboration with US biotech pioneer Amgen, a partnership with a potential value of up to US$618 million.
Amgen has agreed to acquire Dark Blue Therapeutics in a deal valued at up to $840 million, as the biopharmaceutical company continues to build out its early-stage oncology pipeline. The specific breakdown of the upfront payment alongside development and regulatory milestones was not disclosed in the press release.
Dr Rob Scott, former Chief Medical Officer and Head of Development at AbbVie, joined Abionyx Pharma in January as new CMO and Head of Research and Development.